Download PDF
Thromb Haemost 2001; 86(04): 1065-1069
DOI: 10.1055/s-0037-1616534
Special Article
Schattauer GmbH

Both the High Affinity Thrombin Receptor (GPIb-IX-V) and GPIIb/IIIa Are Implicated in Expression of Thrombin-induced Platelet Procoagulant Activity

Ira B. Dicker
1   DuPont Pharmaceuticals Company, Wilmington, DE, USA
,
Donna L. Pedicord
1   DuPont Pharmaceuticals Company, Wilmington, DE, USA
,
Dietmar A. Seiffert
1   DuPont Pharmaceuticals Company, Wilmington, DE, USA
,
G.A. Jamieson
2   American Red Cross, Rockville, MD, USA
,
Nicholas J. Greco
2   American Red Cross, Rockville, MD, USA
› Author Affiliations
Further Information

Publication History

Received 02 August 2000

Accepted after resubmission 06 June 2001

Publication Date:
09 December 2017 (online)

    Permissions and Reprints

Summary

Platelets activated by -thrombin express surface procoagulant activity (PCA) that accelerates the conversion of prothrombin to α-thrombin. Following activation with 10 nM α-thrombin, the PCA of normal platelets was approximately five-fold higher than that of Bernard-Soulier platelets (lacking GPIb). Normal platelet PCA was inhibited ~50 % by activation in the presence of the anti-GPIb MoAbs LJIb10 or TM60. Moreover, normal platelet PCA was completely abrogated in the presence of a combination of both LJIb10 and c7E3, a MoAb directed against αIIbβ3 (GPIIb/IIIa). In contrast, PCA expressed by Bernard Soulier or Glanzmann platelets was not inhibited by either LJIb10 or c7E3 MoAb. The platelet activating peptide SFLLRN at 10 μM, a concentration which fully activates platelet aggregation and Ca2+ mobilization, generated PCA activity one fifth of that generated by α-thrombin at 10 nM but anti-PAR1 antibodies did not affect thrombin-induced PCA expression. These results demonstrate that GPIb mediates, at least in part, the thrombin-induced activation of platelets that leads to PCA, and that αIIbβ3 is also involved in PCA generation, but these results do not support a major role for PAR1 in this activation.

Keywords

Procoagulant - glycoprotein Ib - thrombin
 

  • References

  • 1 Walsh PN, and Schmaier AH. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. Robert W. Colman, Jack Hirsh, Victor J. Marder, Edwin W. Salzman, eds. Lippincott Williams & Wilkins Publishers; Third Edition 1994
    Google Scholar
  • 2 Jamieson GA. Pathophysiology of platelet thrombin receptors. Thromb Haemost 1997; 78: 242-6.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 3 Vu TK, Hung DT, Wheaton VI, Coughlin SR. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell 1991; 64: 1057-68.
    CrossrefPubMedGoogle Scholar
  • 4 Rasmussen UB, Vouret-Craviari V, Jallat S, Schlesinger Y, Pages G, Pavirani A, Lecocq JP, Pouyssegur J, Van Obberghen-Schilling E. cDNA cloning and expression of a hamster alpha-thrombin receptor coupled to Ca2+ mobilization. FEBS Lett 1991; 288: 123-8.
    CrossrefPubMedGoogle Scholar
  • 5 Greco NJ, Tandon NN, Jones GD, Kornhauser R, Jackson B, Yamamoto N, Tanoue K, Jamieson GA. Contributions of glycoprotein Ib and the seven transmembrane domain receptor to increases in platelet cytoplasmic (Ca2+) induced by alpha-thrombin. Biochemistry 1996; 35: 906-14.
    CrossrefPubMedGoogle Scholar
  • 6 Kahn ML, Nakanishi-Matsui M, Shapiro MJ, Ishihara H, Coughlin SR. Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin. J Clin Invest 1999; 103: 879-87.
    CrossrefPubMedGoogle Scholar
  • 7 Andersen H, Greenberg DL, Fujikawa K, Xu W, Chung DW, Davie EW. Protease-activated receptor 1 is the primary mediator of thrombin-stimulated platelet procoagulant activity. Proc Natl Acad Sci 1999; 96: 11189-93.
    CrossrefPubMedGoogle Scholar
  • 8 Lau LF, Pumiglia K, Cote YP, Feinstein MB. Thrombin-receptor agonist peptides, in contrast to thrombin itself, are not full agonists for activation and signal transduction in human platelets in the absence of platelet-derived secondary mediators. Biochem J 1994; 303: 391-400.
    CrossrefPubMedGoogle Scholar
  • 9 Kramer RM, Roberts EF, Hyslop PA, Utterback BG, Hui KY, Jakubowski JA. Differential activation of cytosolic phospholipase A2 (cPLA2) by thrombin and thrombin receptor agonist peptide in human platelets. Evidence for activation of cPLA2 independent of the mitogen-activated protein kinases ERK1/2. J Biol Chem 1995; 270: 14816-23.
    CrossrefPubMedGoogle Scholar
  • 10 Connolly AJ, Ishihara H, Kahn ML, Farese Jr RV, Coughlin SR. Role of the thrombin receptor in development and evidence for a second receptor. Nature 1996; 381: 516-9.
    CrossrefPubMedGoogle Scholar
  • 11 Darrow AL, Fung-Leung WP, Ye RD, Santulli RJ, Cheung WM, Derian CK, Burns CL, Damiano BP, Zhou L, Keenan CM, Peterson PA, Andrade-Gordon P. Biological consequences of thrombin receptor deficiency in mice. Thromb Haemost 1996; 76: 860-6.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 12 Goodwin CA, Wheeler-Jones CP, Kakkar VV, Deadman JJ, Authi KS, Scully MF. Thrombin receptor activating peptide does not stimulate platelet procoagulant activity. Biochem Biophys Res Commun 1994; 202: 321-7.
    CrossrefPubMedGoogle Scholar
  • 13 Kinlough-Rathbone RL, Perry DW, Guccione MA, Rand ML, Packham MA. Degranulation of human platelets by the thrombin receptor peptide SFLLRN: comparison with degranulation by thrombin. Thromb Haemost 1993; 70: 1019-23.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 14 Pedicord DL, Thomas BE, Mousa SA, Dicker IB. Glycoprotein IIb/IIIa receptor antagonists inhibit the development of platelet procoagulant activity. Thromb Res 1998; 90: 247-58.
    CrossrefPubMedGoogle Scholar
  • 15 Lages B, Scrutton MC, Holmsen H. Studies on gel-filtered human platelets: isolation and characterization in a medium containing no added Ca2+, Mg2+, or K+ . J Lab Clin Med 1975; 85: 811-25.
    PubMedGoogle Scholar
  • 16 Jamieson GA, Okumura T. Reduced thrombin binding and aggregation in Bernard-Soulier platelets. J Clin Invest 1978; 61: 861-4.
    CrossrefPubMedGoogle Scholar
  • 17 Alessio M, Greco NJ, Primo L, Ghigo D, Bosia A, Tandon NN, Ocken-house CF, Jamieson GA, Malavasi F. Platelet activation and inhibition of malarial cytoadherence by the anti-CD36 IgM monoclonal antibody NL07. Blood 1993; 82: 3637-47.
    PubMedGoogle Scholar
  • 18 Sims PJ, Wiedmer T, Esmon CT, Weiss HJ, Shattil SJ. Assembly of the platelet prothrombinase complex is linked to vesiculation of the platelet plasma membrane. Studies in Scott syndrome: an isolated defect in platelet procoagulant activity. J Biol Chem 1989; 264: 17049-57.
    PubMedGoogle Scholar
  • 19 Rosing J, van Rijn JL, Bevers EM, van Dieijen G, Comfurius P, Zwaal RF. The role of activated human platelets in prothrombin and factor X activation. Blood 1985; 65: 319-32.
    PubMedGoogle Scholar
  • 20 Miletich JP, Jackson CM, Majerus PW. Interaction of coagulation factor Xa with human platelets. Proc Natl Acad Sci USA 1977; 74: 4033-6.
    CrossrefPubMedGoogle Scholar
  • 21 Barrow RT, Parker ET, Krishnaswamy S, Lollar P. Inhibition by heparin of the human blood coagulation intrinsic pathway factor X activator. J Biol Chem 1994; 269: 26796-800.
    PubMedGoogle Scholar
  • 22 Yamamoto N, Kitagawa H, Tanoue K, Yamazaki H. Monoclonal antibody to glycoprotein Ib inhibits both thrombin- and ristocetin-induced platelet aggregations. Thromb Res 1985; 39: 751-9.
    CrossrefPubMedGoogle Scholar
  • 23 Bevers EM, Comfurius P, Nieuwenhuis HK, Levy-Toledano S, Enouf J, Belluci S, Caen JP, Zwaal RF. Platelet prothrombin converting activity in hereditary disorders of platelet function. Br J Haematol 1986; 63: 335-45.
    PubMedGoogle Scholar
  • 24 Byzova TV, Plow EF. Networking in the hemostatic system. Integrin αIIbβ3 binds prothrombin and influences its activation. J Biol Chem 1997; 272: 27183-8.
    CrossrefPubMedGoogle Scholar
  • 25 Keularts IM, Beguin S, de Zwaan C, Hemker HC. Treatment with a GPIIb/IIIa antagonist inhibits thrombin generation in platelet rich plasma from patients. Thromb Haemost 1998; 80: 370-1.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 26 Reverter JC, Beguin S, Kessels H, Kumar R, Hemker HC, Coller BS. Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and “clinical restenosis.” J Clin Invest 1996; 98: 863-74.
    PubMedGoogle Scholar
  • 27 Herault JP, Peyrou V, Savi P, Bernat A, Herbert JM. Effect of SR121566A, a potent GP IIb-IIIa antagonist on platelet-mediated thrombin generation in vitro and in vivo. Thromb Haemost 1998; 79: 383-8.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 28 Weiss HJ, Lages B. Platelet prothrombinase activity and intracellular calcium responses in patients with storage pool deficiency, glycoprotein IIb-IIIa deficiency, or impaired platelet coagulant activity – a comparison with Scott syndrome. Blood 1997; 89: 1599-611.
    PubMedGoogle Scholar
  • 29 Coller BS. A new murine monoclonal antibody reports an activation-dependent change in the conformation and/or microenvironment of the platelet glycoprotein IIb/IIIa complex. J Clin Invest 1985; 76: 101-8.
    CrossrefPubMedGoogle Scholar
  • 30 Longhurst CM, White MM, Wilkinson DA, Jennings LK. A CD9, αIIbβ3, integrin-associated protein and GPIb-IX-V complex on the surface of platelets is influenced by αIIbβ3 conformational states. Eur J Biochem 1999; 263: 104-11.
    CrossrefPubMedGoogle Scholar